Gufic Biosciences gets DCGI nod for Thymosin Alpha-1 in Covid-19
Gufic Biosciences has secured approval from the Drugs Controller General of India (DCGI) for Thymosin Alpha-1 (Immunocin α) as an add-on therapy for the treatment of moderate-to-severe Covid-19 patients needing ventilator support (NIV and mechanical ventilation). Immunocin α, which is an immuno-modulator drug, considerably cut down the risk of death in phase 3 clinical trial […]